Assessment of anti-CD69 antibody therapy alone or in combination with anti-PD-1 in murine GBM
This is the first study evaluating anti-CD69 therapy in a preclinical GBM model. Despite promising preclinical data in other cancers, anti-CD69 monotherapy or combination therapy with anti-PD-1 did not improve survival in this GBM model.
Authors
- Michal Nisnboym (ORCID: https://orcid.org/0000-0003-0292-6344)
- Stephen C. Frederico (ORCID: https://orcid.org/0000-0003-0232-9187)
- Chaim T. Sneiderman (ORCID: https://orcid.org/0009-0007-3726-6143)
- Gary Kohanbash (ORCID: https://orcid.org/0000-0002-3953-8022)
- Baoli Hu (ORCID: https://orcid.org/0000-0002-2737-6871)
- Sarah R. Vincze (ORCID: https://orcid.org/0009-0003-0735-6827)
- Sameer Agnihotri (ORCID: https://orcid.org/0000-0001-6584-3795)
- Zujian Xiong
- Itay Raphael (ORCID: https://orcid.org/0000-0002-7369-2752)
- ReidAnn E. Sever (ORCID: https://orcid.org/0009-0007-7063-2600)
- Ian F. Pollack (ORCID: https://orcid.org/0000-0003-1765-357X)
- Ambika P. Jaswal (ORCID: https://orcid.org/0000-0002-1929-0082)
- Jan Drappatz (ORCID: https://orcid.org/0000-0001-8187-7119)
- Han Zou
Institutions
- Tel Aviv University (IL)
- University of Pittsburgh (US)
- Tel Aviv Sourasky Medical Center (IL)
- Duke Medical Center (US)
- UPMC Hillman Cancer Center (US)
- Children's Hospital of Pittsburgh (US)
- Duke University Hospital (US)
- Neurological Surgery (US)
Publication Details
- Journal
- Expert Review of Clinical Immunology
- Published
- 2024-10-14
- DOI
- https://doi.org/10.1080/1744666x.2024.2412770
- Citations
- 1
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.45